Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,073.00DKK
7:36am EST
Change (% chg)

kr.-37.00 (-3.33%)
Prev Close
kr.1,110.00
Open
kr.1,116.00
Day's High
kr.1,116.00
Day's Low
kr.1,053.00
Volume
337,557
Avg. Vol
275,358
52-wk High
kr.1,489.00
52-wk Low
kr.1,053.00

Chart for

About

Genmab A/S is a Denmark-based biotechnology company. It is engaged in the development of differentiated human antibody therapeutics for the treatment of cancer, as well as other medical conditions, such as relapsing remitting multiple sclerosis. Its product pipeline includes a number of research and development projects in... (more)

Overall

Beta: 1.29
Market Cap(Mil.): kr.67,916.10
Shares Outstanding(Mil.): 61.19
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 188.50 15.25
EPS (TTM): -- -- --
ROI: -- -11.67 33.27
ROE: -- -36.21 16.35

BRIEF-Biotech Genmab sees 2018 expense growth of 40-50 pct

Dec 12 FOLLOWING ARE STATEMENTS FROM GENMAB'S R'N'D UPDATE IN ATLANTA, GEORGIA:

Dec 12 2017

Genmab and Johnson & Johnson 'love' partnership as some ponder takeover

LONDON Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion this year and propelled the Danish antibody specialist to the top spot.

Nov 30 2017

Europe's top biotech expects delays from drugs watchdog's HQ move

LONDON Europe's biggest biotechnology company, Denmark's Genmab, expects some delays to regional drug approvals as the European Medicines Agency is uprooted from London to Amsterdam.

Nov 30 2017

Europe's top biotech expects delays from drugs watchdog's HQ move

LONDON Europe's biggest biotechnology company, Denmark's Genmab, expects some delays to regional drug approvals as the European Medicines Agency is uprooted from London to Amsterdam.

Nov 30 2017

Europe's top biotech expects delays from drugs watchdog's HQ move

LONDON, Nov 30 Europe's biggest biotechnology company, Denmark's Genmab, expects some delays to regional drug approvals as the European Medicines Agency is uprooted from London to Amsterdam.

Nov 30 2017

BRIEF-Genmab Achieves $20 Million Milestone In Daratumumab Collaboration With Janssen

* GENMAB ACHIEVES USD 20 MILLION MILESTONE IN DARATUMUMAB COLLABORATION WITH JANSSEN AND UPDATES FINANCIAL GUIDANCE

Nov 29 2017

Johnson & Johnson drug succeeds in newly diagnosed multiple myeloma patients: study

Johnson & Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.

Nov 21 2017

UPDATE 2-J&J drug succeeds in newly diagnosed multiple myeloma patients-study

Nov 21 Johnson & Johnson's blockbuster multiple myeloma drug Darzalex when added to a standard therapy regimen reduced the risk of disease progression or death by 50 percent compared with standard therapy alone in patients not previously treated for the blood cancer, according to data released on Tuesday.

Nov 21 2017

BRIEF-Genmab gets USD 3 million in milestone payments from Janssen

* ‍GENMAB TO RECEIVE USD 3 MILLION IN MILESTONE PAYMENTS FROM JANSSEN​

Nov 21 2017

BRIEF-Genmab: $50 mln milestone payment in collaboration on Darzalex

* SAID ON FRIDAY WILL RECEIVE MILESTONE PAYMENT OF USD 50 MILLION IN DARZALEX COLLABORATION WITH JANSSEN BIOTECH, INC.

Nov 17 2017

Earnings vs. Estimates